Welcome to our dedicated page for Prime Medicine news (Ticker: PRME), a resource for investors and traders seeking the latest updates and insights on Prime Medicine stock.
Prime Medicine, Inc. develops genetic medicines using its proprietary Prime Editing platform, which is designed to make targeted edits within genes. News about PRME centers on its pipeline for genetically defined diseases, including PM577 for Wilson Disease, PM647 for Alpha-1 Antitrypsin Deficiency and PM359, an investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease.
Company updates also cover financial results, regulatory interactions, clinical-data publications, investor conference participation and finance leadership changes. Additional recurring themes include an in vivo cystic fibrosis program supported by the Cystic Fibrosis Foundation and Prime Edited CAR-T product development with Bristol Myers Squibb for hematology, immunology and oncology.
Prime Medicine (Nasdaq: PRME) has announced the pricing of a public offering of 38,000,000 shares of common stock at $3.30 per share. The biotechnology company expects to raise approximately $125.4 million in gross proceeds before deducting expenses.
The offering includes a notable arrangement with the Cystic Fibrosis Foundation, which will purchase 1,818,181 shares without underwriter commissions. Additionally, underwriters have a 30-day option to purchase up to 5,700,000 additional shares. The offering is expected to close around August 1, 2025, with TD Cowen and BMO Capital Markets serving as joint book-running managers.
Prime Medicine (Nasdaq: PRME), a biotechnology company focused on curative genetic therapies, has announced a proposed public offering of common stock. The company will grant underwriters a 30-day option to purchase an additional 15% of the offered shares.
The offering will be managed by TD Cowen and BMO Capital Markets as joint book-running managers. The shares will be offered through a previously filed shelf registration statement that became effective on November 13, 2023. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
Prime Medicine (Nasdaq: PRME) has secured up to $24 million in additional funding from the Cystic Fibrosis Foundation to accelerate the development of Prime Editors for treating cystic fibrosis (CF). The funding includes a $6 million equity investment and will be provided in two tranches, subject to certain conditions and milestones.
The company's Prime Editing technology aims to permanently correct CF-related lung disease through multiple hotspot Prime Editors that could potentially benefit over 93% of CF patients. Initially, Prime Medicine will focus on targeting the G542X mutation, one of the most common CF-causing nonsense mutations currently lacking available therapies.
Prime Medicine (NASDAQ: PRME), a biotechnology company focused on developing one-time curative genetic therapies, has announced its participation in two major upcoming investor conferences. The company will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 10:30 a.m. ET in New York, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 2:40 p.m. ET in Miami Beach. Both presentations will be available via live audio webcasts on the company's website, with replays accessible for 90 days following each event.
Prime Medicine (Nasdaq: PRME) has unveiled a preclinical program for treating alpha-1 antitrypsin deficiency (AATD), marking their second liver franchise program. The company plans to file an IND/CTA in mid-2026.
The program utilizes Prime's proprietary universal liver lipid nanoparticle (LNP) to edit the E342K (Pi*Z) mutation in the SERPINA1 gene. Initial in vivo data showed up to 72% precise correction of the SERPINA1 gene in hepatocytes of humanized mice, restoring over 95% of serum AAT to the corrected isoform with healthy AAT protein levels above 20µM.
Preclinical studies using unoptimized surrogate Prime Editors in non-human primate models demonstrated greater than 50% editing with an excellent safety profile and no detectable off-target edits. The company expects to advance both AATD and Wilson's Disease programs toward clinical data in 2027.
Prime Medicine (NASDAQ: PRME) has reported its full year 2024 financial results and provided key business updates. The company is progressing with its Phase 1/2 clinical trial of PM359 for p47phox CGD, with initial data expected in 2025. Their Wilson's Disease program (PM577) is advancing through IND-enabling studies, targeting IND/CTA filing in 1H 2026.
Financial highlights for 2024 include:
- R&D expenses increased to $155.3 million (from $147.9M in 2023)
- G&A expenses rose to $50.2 million (from $43.4M in 2023)
- Net loss was $195.9 million (improved from $198.1M in 2023)
- Cash position strengthened to $204.5 million (up from $135.2M in 2023)
The company expects its current cash position to fund operations into the first half of 2026.
Prime Medicine (Nasdaq: PRME), a biotechnology company focused on developing one-time curative genetic therapies, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's President and CEO, Keith Gottesdiener, M.D., will engage in a fireside chat on Monday, March 3, 2025, at 11:10 a.m. ET in Boston, MA.
The presentation will be accessible through a live audio webcast in the 'Events & Presentations' section of Prime Medicine's website. Interested parties can access the replay of the webcast on the company's website for 30 days after the presentation.